PALI today
$1.17-$0.00 (-0.43%)close Nov 12, 2026Trend
DailyDowntrend (confirmed)
4 hourLeaning Bullish
1 hourSymmetric Triangle
15 minStrong Bullish
5 minStrong Bullish
Daily trend turns up above $1.63
Key levels
Resistance$1.38
Resistance$1.25
Support$1.10
Support$0.80
Latest news & SEC filings
AnalystPalisade Bio Analysts Lower Forecasts Following Q3 Results
AnalystPiper Sandler keeps Overweight on Palisade Bio, cuts price target to $16
EarningsPalisade Bio Posts Q3 2026 Results, Gives Business Update
AnalystHC Wainwright keeps Buy rating on Palisade Bio, cuts target to $5
All PALI news →About Palisade Bio
Palisade Bio is a drug developer working on pills that stay inactive until they reach the lower gut, where they release a compound that dampens inflammation. Its main experimental medicine, PALI-2108, is being studied in people with chronic gut conditions such as ulcerative colitis and Crohn's disease, and in those with intestinal scarring. The company conducts trials in Canada and the United States and uses outside manufacturers for its clinical supplies.
Based on the company's 10-K filed Mar 20, 2026.
Nasdaq · Healthcare
PALISADE BIO, INC. (PALI)
What Is the Price Target for PALI?
SEPT Low Target
$5.00
SEPT Mid Target
$7.00
SEPT High Target
$8.00
Analyst Consensus
$7.00
Is PALI a Buy or Sell Right Now?
Thesis
- •Smart money flows are positive — institutional and insider activity shows net buying.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for PALI.
Start Free Trial →Is PALI Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
PEG, Analyst Consensus
Fair Value
$5.04
12
Moat Score
NONE
4/9
Piotroski Score
8.3
Altman Z-Score
What Is Smart Money Doing with PALI?
Insider Signal
BUYING
4 buys / 2 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Capers Julien E. | officer | Buy | 787,300 | - | Oct 19, 2026 |
| Jones Mitchell Lawrence | officer | Buy | 2,620,850 | - | Oct 6, 2026 |
| Jones Mitchell Lawrence | officer | Sale | 1,031,102 | $1.5M | Oct 6, 2026 |
| Finley John David | director officer | Buy | 3,227,384 | - | Oct 6, 2026 |
| Finley John David | director officer | Sale | 1,411,982 | $2.1M | Oct 6, 2026 |
| Williams Donald Allen | director | Buy | 10,000 | $15K | Oct 2, 2026 |
| Williams Donald Allen | director | Buy | 10,000 | $14K | Oct 1, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →PALI Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
97.06%
FCF Growth YoY
N/A%
Revenue Trend
UNKNOWN
Dark Pool Trades for PALI
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for PALI, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 16:55:25 | $1.16 | 1,300 | $$2K | SELL |
| 16:50:48 | $1.17 | 4,756 | $$6K | BUY |
| 16:47:47 | $1.17 | 1,128 | $$1K | BUY |
| 16:47:47 | $1.17 | 1,623 | $$2K | MIDPOINT |
| 16:45:38 | $1.16 | 2,600 | $$3K | BUY |
5 dark pool trades shown · $$13K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for PALISADE BIO, INC. (PALI) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (4 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →PALI — frequently asked questions
What is PALI stock price today?
PALISADE BIO, INC. (PALI) is at $1.17, down 0.43% (-$0.00) at the Nov 12, 2026 close.
Why is PALI stock down today?
Nov 11, 2026: Palisade Bio shares closed at $1.17, up 5.41% on volume of 2.94 million shares, despite a pair of bearish analyst actions tied to the company's third-quarter results. Analysts lowered their forecasts following the Q3 report, and Piper Sandler maintained its Overweight rating but cut its price target to $16.
What is the PALI price target?
The average analyst price target for PALI is $7.00, ranging from $5 to $8, based on 6 analysts. Latest: HC Wainwright & Co. maintains on Nov 11, 2026.
What do analysts rate PALI?
Analyst ratings for PALI: 0 Buy, 8 Hold, 0 Sell — consensus Hold.
Did PALI beat earnings?
PALI last reported on Nov 10, 2026: EPS -$0.07 vs -$0.06 expected — a miss of 16.7%.
What is PALI's P/E ratio?
PALI trades at a P/E of 1.8 vs a Healthcare average of 17.7.
Does PALI pay a dividend?
PALI does not currently pay a dividend.
What are PALI support and resistance levels?
Support: $1.10, $0.80, $0.69. Resistance: $1.25, $1.38, $1.51.
What are insiders doing with PALI?
Insider activity: BUYING, 4 buys and 2 sells in the last 90 days.
What is the latest news on PALI?
Nov 11, 2026: Palisade Bio Analysts Lower Forecasts Following Q3 Results · Nov 11, 2026: Piper Sandler keeps Overweight on Palisade Bio, cuts price target to $16 · Nov 11, 2026: Palisade Bio Posts Q3 2026 Results, Gives Business Update